We also demonstrated that C-C chemokine motif ligand 5 (CCL5) is responsible for maintaining CAF activation, and neutralizing CCL5 could attenuate PARPi-induced CAF activation in vitro and in both BRCA1/2-wild type and BRCA1/2-mutant xenograft models and boost the tumor inhibitory effect of PARPis. The gene discussed is CCL5; the disease is neoplasm.